Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beyond AirXAIR -11.80%25 EV-to-EBITDA is -0.64 as of Aug. 16, 2026. GuruFocus rates XAIR with a GF Score™ of 25/100 and a GF Value™ of $134.81 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Beyond Air ranks worse than 194931.58% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beyond Air's enterprise value is $17.37 Mil.
Beyond Air's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-27.17 Mil. Therefore, Beyond Air's EV-to-EBITDA for today is -0.64.
The historical rank and industry rank for Beyond Air's EV-to-EBITDA or its related term are showing as below:
XAIR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.1 Med: -2.91 Max: -0.04
Current: -0.64
During the past 12 years, the highest EV-to-EBITDA of Beyond Air was -0.04. The lowest was -13.10. And the median was -2.91.
XAIR's EV-to-EBITDA is ranked worse than 100% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs XAIR: -0.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beyond Air's share price for today is $6.25.
Beyond Air's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Beyond Air's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Beyond Air's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Beyond Air's EV-to-EBITDA falls into.
Beyond Air's current Enterprise Value is $17.37 Mil.
Beyond Air's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air (XAIR) has a EV-to-EBITDA of -0.64 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beyond Air. According to the industry distribution chart, Beyond Air ranks #999999 out of 513 companies in the Medical Devices & Instruments industry.
Is Beyond Air's EV-to-EBITDA too high?
Beyond Air's current EV-to-EBITDA is -0.64. Based on the distribution chart, Beyond Air ranks #999999 out of 513 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Beyond Air has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's EV-to-EBITDA compare to POAS and RMSL?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #999999 out of 513 companies for EV-to-EBITDA. This places Beyond Air in the lower half of its industry. The industry median EV-to-EBITDA is 14.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beyond Air. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beyond Air's current EV-to-EBITDA is -0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Based on GuruFocus' analysis, Beyond Air (XAIR) is currently considered Possible Value Trap. The stock's GF Value™ is $134.81, compared to a current price of $6.25 — trading 95.4% below its estimated fair value. The current EV-to-EBITDA is -0.64. Beyond Air's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Beyond Air (XAIR), the current EV-to-EBITDA is -0.64 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beyond Air (XAIR) Overvalued in 2026?
Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued.
The current stock price of $6.25 is trading 95.4% below its estimated GF Value™ of $134.81.
GuruFocus considers Beyond Air to be Possible Value Trap.
Key valuation signals for XAIR:
EV-to-EBITDA: -0.64
GF Value™: $134.81 vs. price of $6.25 (95.4% below fair value)
No single metric tells the full story. See the XAIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
25GF Score
Get the complete analysis for XAIR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAIR has been successfully added to your 
